A Case Report of Immune Checkpoint-Related Hemophagocytic Lymphohistiocytosis and Review of the Literature.

IF 0.7 Q4 ONCOLOGY Case Reports in Oncology Pub Date : 2024-07-30 eCollection Date: 2024-01-01 DOI:10.1159/000539955
Michael Herman, Andrea Lee, Sandra Fawcett, Sanjeev Deodhare
{"title":"A Case Report of Immune Checkpoint-Related Hemophagocytic Lymphohistiocytosis and Review of the Literature.","authors":"Michael Herman, Andrea Lee, Sandra Fawcett, Sanjeev Deodhare","doi":"10.1159/000539955","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hemophagocytic lymphohistiocytosis (HLH) secondary to immune checkpoint inhibitors (irHLH) is rare, and consequently optimal management strategies remain to be defined. There are sparse reports of the successful treatment of irHLH with steroids and tocilizumab. This case adds to the body of literature supporting this management strategy.</p><p><strong>Case description: </strong>We present a case of a patient with thoracic malignancy who received dual checkpoint inhibitors and developed weakness, fever, confusion, and cytopenias. Further testing revealed an extremely elevated ferritin level. Cytokine levels as well as HLH-2004 criteria and HScore results were consistent with irHLH. Clinical parameters and symptoms promptly improved after the administration of corticosteroids and tocilizumab.</p><p><strong>Conclusion: </strong>This case highlights an important treatment strategy for an immune checkpoint inhibitor toxicity associated with a high mortality rate.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324240/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000539955","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Hemophagocytic lymphohistiocytosis (HLH) secondary to immune checkpoint inhibitors (irHLH) is rare, and consequently optimal management strategies remain to be defined. There are sparse reports of the successful treatment of irHLH with steroids and tocilizumab. This case adds to the body of literature supporting this management strategy.

Case description: We present a case of a patient with thoracic malignancy who received dual checkpoint inhibitors and developed weakness, fever, confusion, and cytopenias. Further testing revealed an extremely elevated ferritin level. Cytokine levels as well as HLH-2004 criteria and HScore results were consistent with irHLH. Clinical parameters and symptoms promptly improved after the administration of corticosteroids and tocilizumab.

Conclusion: This case highlights an important treatment strategy for an immune checkpoint inhibitor toxicity associated with a high mortality rate.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
免疫检查点相关嗜血细胞淋巴组织细胞增多症病例报告及文献综述。
导言:继发于免疫检查点抑制剂的嗜血细胞淋巴组织细胞增多症(HLH)(irHLH)非常罕见,因此最佳治疗策略仍有待确定。关于使用类固醇和托珠单抗成功治疗irHLH的报道很少。本病例补充了支持这一治疗策略的文献:我们介绍了一例胸部恶性肿瘤患者的病例,该患者接受了双重检查点抑制剂治疗后出现了虚弱、发热、精神错乱和细胞减少症。进一步检测发现铁蛋白水平极度升高。细胞因子水平以及HLH-2004标准和HScore结果与irHLH一致。在使用皮质类固醇和托珠单抗后,临床指标和症状迅速得到改善:本病例强调了针对与高死亡率相关的免疫检查点抑制剂毒性的一种重要治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.40
自引率
12.50%
发文量
151
审稿时长
7 weeks
期刊最新文献
Parathyroid Hormone-Related Protein-Producing Adenocarcinoma Suspicious of Lung Cancer: A Case Report. Primary Small Bowel Adenocarcinoma with Metastatic Ovarian Tumor in a Pregnant Woman. Enfortumab Vedotin-Induced Febrile Neutropenia and Hyperglycemia Successfully Treated with Multidisciplinary Treatment Including Continuous Hemodialysis Filtration and Insulin Injection in a Patient with Chemo-Resistant Metastatic Urothelial Carcinoma: A Case Report. Unusual Synchronous Multiple Primary Early-Stage Lung Adenocarcinoma with Concomitant MET Exon 14 Skipping, PIK3CA and KRAS Mutations: A Case Report. Complete Response to Pembrolizumab in a Patient with Castration-Resistant Prostate Cancer with Both BRCA Positivity and a High Frequency of Microsatellite Instability: A Case Report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1